These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

59 related articles for article (PubMed ID: 2109560)

  • 21. [Blood level profile of valproate administration under therapeutic conditions in children].
    Meyer FP; Sauer I; Staemmler U; Walther H
    Padiatr Grenzgeb; 1990; 29(4):325-30. PubMed ID: 2216528
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Non-steroidal anti-inflammatory drugs and the protective activity of valproate and diphenylhydantoin against maximal electroshock-induced seizures in mice--an interaction.
    Kozicka M; Kamiński R; Parada-Turska J; Dziki M; Kleinrok Z; Turski WA; Czuczwar SJ
    Pol J Pharmacol; 1998; 50(1):94-5. PubMed ID: 9662751
    [No Abstract]   [Full Text] [Related]  

  • 23. A pharmacokinetic study to determine the drug interaction between valproate and propranolol.
    Nemire RE; Toledo CA; Ramsay RE
    Pharmacotherapy; 1996; 16(6):1059-62. PubMed ID: 8947979
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical and pharmacokinetic observations on valproate: a 3 year follow-up study in 100 children with generalized epilepsy.
    Steinborn B; Galas-Zgorzalewicz B
    Funct Neurol; 1993; 8(6):415-22. PubMed ID: 8150320
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Valproic acid-amitriptyline interaction in man.
    Pisani F; Primerano G; Amendola D'Agostino A; Spina E; Fazio A
    Ther Drug Monit; 1986; 8(3):382-3. PubMed ID: 3092410
    [No Abstract]   [Full Text] [Related]  

  • 26. [Plasma levels of valproic acid].
    de la Morena García E; Borges Domingo MT
    Rev Clin Esp; 1983 Apr; 169(2):91-3. PubMed ID: 6410464
    [No Abstract]   [Full Text] [Related]  

  • 27. High-dose sodium valproate therapy for childhood refractory epilepsy.
    Amano R; Mizukawa M; Ohtsuka Y; Ohtahara S
    Jpn J Psychiatry Neurol; 1990 Jun; 44(2):343-4. PubMed ID: 2124287
    [No Abstract]   [Full Text] [Related]  

  • 28. Valproic acid and thrombocytopenia. Case report.
    Patel CC; Church S; Reilly KM
    J Ky Med Assoc; 1982 Apr; 80(4):213-5. PubMed ID: 6808068
    [No Abstract]   [Full Text] [Related]  

  • 29. [Sodium valproate--still a current antiepileptic agent?].
    Scollo-Lavizzari G; Proeckl D
    Praxis (Bern 1994); 1994 Oct; 83(40):1098-105. PubMed ID: 7939080
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Somnambulism due to probable interaction of valproic acid and zolpidem.
    Sattar SP; Ramaswamy S; Bhatia SC; Petty F
    Ann Pharmacother; 2003 Oct; 37(10):1429-33. PubMed ID: 14519043
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetic Interaction Between Valproic Acid, Meropenem, and Risperidone.
    Paulzen M; Eap CB; Gründer G; Kuzin M
    J Clin Psychopharmacol; 2016 Feb; 36(1):90-2. PubMed ID: 26658079
    [No Abstract]   [Full Text] [Related]  

  • 32. Single-dose model for predicting steady-state valproic acid serum concentrations in seizure patients.
    Pugh CB; Garnett WR; Poynor WJ; Pellock JM
    Clin Pharm; 1984; 3(6):643-9. PubMed ID: 6439455
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Relative bioavailability and stability of extemporaneously prepared valproic acid emulsion.
    Veerman MW; Hatton RC; Knight ME
    Clin Pharm; 1991 May; 10(5):382-4. PubMed ID: 2049900
    [No Abstract]   [Full Text] [Related]  

  • 34. Serum valproate concentrations and control of seizures.
    Addy DP
    J Pediatr; 1992 Nov; 121(5 Pt 1):835-6. PubMed ID: 1432445
    [No Abstract]   [Full Text] [Related]  

  • 35. Breakthrough seizure following substitution of Depakene capsules (Abbott) with a generic product.
    MacDonald JT
    Neurology; 1987 Dec; 37(12):1885. PubMed ID: 3120036
    [No Abstract]   [Full Text] [Related]  

  • 36. Erythromycin and valproate interaction.
    Redington K; Wells C; Petito F
    Ann Intern Med; 1992 May; 116(10):877-8. PubMed ID: 1567109
    [No Abstract]   [Full Text] [Related]  

  • 37. Diurnal variation in pharmacokinetics of valproic acid with unequal dosing intervals.
    Johno I; Nakamura T; Horiuchi T; Nadai M; Kitazawa S; Yoshimine N; Kuzuya F
    Chem Pharm Bull (Tokyo); 1988 Jul; 36(7):2551-6. PubMed ID: 3149210
    [No Abstract]   [Full Text] [Related]  

  • 38. Simulated Y-Site Compatibility of Vancomycin and Piperacillin-Tazobactam.
    Wade J; Cooper M; Ragan R
    Hosp Pharm; 2015 May; 50(5):376-9. PubMed ID: 26405323
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Interaction of valproic acid and erythromycin].
    Sánchez Romero A; Onsurbe Ramírez I
    An Esp Pediatr; 1990 Jan; 32(1):78-9. PubMed ID: 2109560
    [No Abstract]   [Full Text] [Related]  

  • 40. Valproic acid.
    Sharma M; Agrawal P
    Indian Pediatr; 1991 Aug; 28(8):921-6. PubMed ID: 1808081
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.